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Abstract
Objective: To identify the causal gene in a multi-incident U.S. kindred with Parkinson’s disease (PD).
Methods: We characterized a family with a classical PD phenotype in which 7 individuals (5 males and 2 females)
were affected with a mean age at onset of 46.1 years (range, 29-57 years). We performed whole exome sequencing
on 4 affected and 1 unaffected family members. Sanger-sequencing was then used to verify and genotype all
candidate variants in the remainder of the pedigree. Cultured cells transfected with wild-type or mutant constructs
were used to characterize proteins of interest.
Results: We identified a missense mutation (c.574G > A; p.G192R) in the RAB39B gene that closely segregated with
disease and exhibited X-linked dominant inheritance with reduced penetrance in females. The mutation occurred
in a highly conserved amino acid residue and was not observed among 87,725 X chromosomes in the Exome
Aggregation Consortium dataset. Sequencing of the RAB39B coding region in 587 familial PD cases yielded two
additional mutations (c.428C > G [p.A143G] and c.624_626delGAG [p.R209del]) that were predicted to be deleterious
in silico but occurred in families that were not sufficiently informative to assess segregation with disease.
Experiments in PC12 and SK-N-BE(2)C cells demonstrated that p.G192R resulted in mislocalization of the mutant protein,
possibly by altering the structure of the hypervariable C-terminal domain which mediates intracellular targeting.
Conclusions: Our findings implicate RAB39B, an essential regulator of vesicular-trafficking, in clinically typical PD.
Further characterization of normal and aberrant RAB39B function might elucidate important mechanisms underlying
neurodegeneration in PD and related disorders.
Background
Parkinson’s disease (PD) is the second most common
neurodegenerative disorder and though approximately
20 % of patients report a family history of the disease,
kindreds that display clear Mendelian inheritance are
rare. However, mutations in several genes have been
shown to result in clinically typical autosomal dominant
(SNCA, LRRK2, VPS35, DNAJC13) or recessive (PARK2,
PINK1, PARK7) PD, or parkinsonism with atypical
features (e.g. PARK9) [1]. Functional characterization of
these genetic variants has provided important insights
into the molecular mechanisms underlying PD and
elucidated novel targets for therapeutic intervention.
Whole-exome sequencing (WES) is a powerful tool for
gene discovery in pedigrees that are not sufficiently large
for traditional linkage analysis [2] and this technique has
been successful in identifying two causal genes for PD
[3, 4]. In this study we present data from WES and
in vitro functional analyses that demonstrate that a
missense mutation (p.G192R) in the RAB39B gene is
the causative variant in a multi-incident family with
clinically typical PD.
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Results
We studied a U.S. family of European origin in which 7
individuals (5 males and 2 females) were affected and
met UK PD Society Brain Bank clinical diagnostic criteria
for PD [5] (Fig. 1a). The clinical characteristics of the
affected family members are provided in Table 1. None of
these individuals displayed atypical findings on neuro-
logical examination but two of them (III-15 and IV-4) had
mild intellectual disability since childhood. DNA was
available for 6 affected and 10 unaffected members of the
family. We performed WES on 4 affected (III-4, III-9,
III-11, and III-18) and 1 unaffected (III-13) family mem-
bers. We filtered out all variants with a frequency >1 % in
515 controls from the NHLBI Exome Sequencing Project
[6, 7] or that failed to meet the quality thresholds of the
Genome Analysis ToolKit (GATK) “Best Practices” [8].
We identified three nonsynonymous variants that passed
all filters, segregated with PD among the 5 individuals
who underwent WES, and were confirmed by Sanger se-
quencing: USP1 c.573G >A (p.M191I), MVP c.2594G > T
(p.G865V), and RAB39B c.574G >A (p.G192R) (Table 2).
We then genotyped these three variants in all remaining
family members and found that only RAB39B p.G192R
was present in all six affected subjects. Furthermore,
RAB39B p.G192R was not observed among 87,725 X
chromosomes successfully sequenced for RAB39B in
the Exome Aggregation Consortium database (ExAC;
http://exac.broadinstitute.org). The amino acid G192
is highly conserved across species (Fig. 1b) and this
mutation is predicted to be deleterious as evidenced
by a Combined Annotation Dependent Depletion (CADD)
[9] score of 29.4.
We then screened for RAB39B p.G192R in 2 cohorts
of PD patients from the Parkinson’s Genetic Research
Study (PaGeR). Cohort I was comprised of 203 “multi-
plex” families ascertained from across the U.S. (mean age
at onset of probands, 57.3 years; male, 61.9 %) in which at
least 2 individuals with PD were enrolled. Cohort II
included 1298 unrelated PD patients (mean age at onset,
59.1 years; male, 69.2 %) enrolled primarily at movement
disorder clinics in the Pacific Northwest regardless of
family history. RAB39B p.G192R was not found in any
other PD patients across PaGeR cohorts I and II
(total n = 1501). We also sequenced the entire RAB39B
coding region in the subset of patients from both PaGeR
cohorts (n = 587) who reported a family history of PD
and discovered two additional mutations, c.428C > G
(p.A143G) and c.624_626delGAG (p.R209del). Neither
Fig. 1 Identification of the RAB39B p.G192R mutation by whole exome sequencing in a multigenerational kindred with Parkinson’s disease.
a Pedigree diagram; individuals affected with Parkinson’s disease are represented with black symbols, unaffected individuals with open symbols.
Age at onset is indicated immediately below each symbol, followed by age at last clinical evaluation. Wt = wild type; Mut =mutation (p.G192R).
b Multispecies protein sequence alignment. Hs = Homo sapiens; Mm =Mus musculus; Dr = Danio rerio (zebrafish); Dm = Drosophila melanogaster;
Ce = Caenorhabditis elegans. c Predicted protein structure of RAB39B using Protein Homology/analogY Recognition Engine V 2.0 (Phyre2; http://
www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index) [23]; 89 % of the amino acid residues were modeled at >90 % confidence. P.G192R is
located in the hypervariable C-terminal domain which is depicted in red
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of these mutations were present in the ExAC dataset
and both are predicted to be deleterious in silico with
CADD scores of 21.8 (p.A143G) and 20.4 (p.R209del).
Each mutation was present in a single family but
neither of the two pedigrees was sufficiently inform-
ative to assess segregation with disease (Additional
file 1: Figure S1).
We then investigated the effects of RAB39B p.G192R
in vitro. In PC12 and SK-N-BE(2)C cells transfected with
mutant and wild-type constructs there was no substan-
tial difference in RAB39B protein expression (Figs. 2a
and 3a). In NGF-differentiated PC12 cells wild-type
RAB39B protein was visualized throughout the cyto-
plasm of cell bodies and neuritic processes (Fig. 2b), and
co-localized with the vesicular marker chromogranin A.
However, mutant (p.G192R) RAB39B was largely re-
stricted to cell bodies with negligible amounts of protein
evident in neuritic processes. In these experiments there
was robust expression of both mutant and wild type
RAB39B protein, but cellular phenotype can sometimes
differ based on the level of transgene over-expression [10].
Thus we used an alternate vector and method of transfec-
tion to over-express RAB39B at lower levels in retinoic
acid-differentiated SK-N-BE(2)C cells. Wild type RAB39B
protein was frequently visualized within the cytoplasm
and at the plasma membrane (co-localized with EGFR;
Fig. 3b). However, while mutant RAB39B protein was also
abundant in the cytoplasm, it was less frequently observed
at the plasma membrane. To quantify these findings we
performed immunoblot analysis of fractionated protein
extracts from these cells (Fig. 3c). The proportion of
membrane-bound to cytosolic RAB39B protein was
significantly lower in cells expressing mutant protein than
wild type protein (p < 0.01).
Discussion
In the present study we provide strong evidence that the
missense mutation p.G192R in RAB39B results in clinic-
ally typical, levodopa responsive PD. The pattern of inher-
itance is X-linked dominant with reduced penetrance
among females. Age at onset varied by nearly three
decades and was lower in males. A single male mutation
Table 1 Clinical characteristics of the affected members of the pedigree
Characteristic Patient
III-4 III-9 III-10 III-11 III-15 III-18 IV-4
Sex F F M M M M M
Age at onset, yr 57 55 29 50 53 31 48
Age at last evaluation, yr 64 62 53 61 58 51 50
Age at death, yr 70 64 56 ─ ─ ─ ─
Bradykinesia Y Y Y Y Y Y Y
Rigidity Y Y Y Y Y Y Y
Resting tremor Y N Y Y Y Y Y
Postural instability Y N Y Y N Y Y
Unilateral onset Y Y Y Y Y Y Y
Levodopa response Y Y Y Y Y Y NT
Levodopa-induced dyskinesia N Y Y Y N Y ─
Mild, lifelong intellectual disability N N N N Y N Y
Hoehn and Yahr stagea 4 3 4 2.5 2 5 2.5
MDS-UPDRS III scorea NA 24 NA 26 19 52 11
MDS-UPDRS III = Movement Disorder Society Unified Parkinson’s Disease Rating Scale Part III; NA = not available; NT = no trial
aDetermined at last evaluation
Table 2 Candidate variants identified by whole exome sequencing
Gene Position (hg19) Transcript dbSNP Variation Allele
frequency (%)a
CADD score Segregationb
Nucleotide Amino acid
USP1 Chr1:62910424 NM_001017415.1 ─ c.573G > A p.M191I 0 27.1 5/6
MVP Chr16:29859222 NM_005115.4 rs151174471 c.2594G > T p.G865V 0.07 7.19 5/6
RAB39B ChrX:154490156 NM_171998.2 ─ c.574G > A p.G192R 0 29.4 6/6
CADD Combined Annotation Dependent Depletion
aFrequency among chromosomes successfully sequenced for USP1 (n = 111,418), MVP (n = 121,248), and RAB39B (n = 87,725) in the Exome Aggregation
Consortium database (http://exac.broadinstitute.org)
bNumber of affected individuals with the variant/total number of affected individuals with genotypes in the pedigree
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carrier was unaffected at age 41. Since his current age is
below the age at onset observed for 3 of the 5 affected
males in the pedigree, he might well become symptomatic
over time. Alternatively, it is possible that the presence of
other genetic or environmental factors are necessary for
p.G192R to achieve full penetrance.
RAB39B was first linked to human disease in 2010
when a nonsense and a splice site mutation in the gene
were shown to cause mental retardation, sometimes
accompanied by epilepsy and autism spectrum disorder,
in the male members of two families [11]. Subsequently,
duplications and triplications of a genomic region con-
taining RAB39B were discovered in males from three
families with a similar phenotype [12]. Recently, two
families were reported with early onset parkinsonism in
males and a missense mutation (p.T168K) or a complete
deletion of RAB39B [13]. An autopsy of one such subject
showed dopaminergic neuron loss in the substantia nigra
and widespread Lewy body pathology. However, affected
individuals all had features that were atypical for PD
including intellectual disability, macrocephaly, and in the
majority of cases, a lack of response to levodopa. In con-
trast, most individuals in our family displayed a classical
PD phenotype, with the exception of two affected males
who had mild intellectual disability, and both males and
females were affected.
The explanation for the wide range of phenotypes
associated with RAB39B mutations is not entirely clear.
Previously reported mutations result in either over-
expression of wild-type protein [12] or a complete loss
of protein expression [11, 13]. However, the mutation
discovered in our family (p.G192R) did not substantially
change the overall amount of RAB39B protein expressed
in PC12 or SK-N-BE(2)C cells. Instead, p.G192R appears
to alter intracellular localization as the mutant protein
did not properly migrate to the neuritic processes of
NGF-differentiated PC12 cells and to the plasma mem-
brane in SK-N-BE(2)C cells. This is consistent with the
structural location of p.G192R based on current know-
ledge of Rab proteins. RAB39B is one of over 60 members
of the human Rab GTPase family [14]. Rab GTPases act
as molecular switches, cycling between active (GTP-
bound) and inactive (GDP-bound) states to regulate intra-
cellular vesicular trafficking in a temporally and spatially
sensitive manner [15]. The C-terminus of Rab proteins
contains a hypervariable domain (HVD) of 35-40 amino
acids which through interactions with effector proteins
plays a major role in targeting each Rab to the appropriate
Fig. 2 Effect of p.G192R on RAB39B expression and localization in PC12 cells. a Western blot of rat pheochromocytoma (PC12) cells transfected
with a vector that was empty (mock), or contained a wild-type or mutant (p.G192R) construct. There was no difference in protein expression
between wild-type and mutant RAB39B. b Immunofluorescent microscopy of nerve growth factor-differentiated PC12 cells transfected with
wild-type or mutant (p.G192R) myc-tagged RAB39B. The wild-type protein is visualized throughout the cell bodies and neuritic processes, together
with the vesicular marker chromogranin A, whereas the mutant protein is largely confined to cell bodies. Arrowheads indicate terminal regions of
neurites. The scale bar corresponds to 10 μm
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intracellular location [14]. The HVD has a high content of
helix-breaking proline and glycine residues which contrib-
ute to the extended structure that allows for necessary
protein interactions [16]. Because p.G192R is located
within the HVD (Fig. 1c) and eliminates one such glycine
moiety the mutation might disrupt proper targeting of
RAB39B by inhibiting binding to effector molecules. Fur-
thermore, the fact that two heterozygous females in our
pedigree were affected raises the possibility that p.G192R
might exert its pathogenic effects through a dominant
negative mechanism. Interestingly, a dominant negative
mutation in another Rab protein (Rab8) has been
described that when introduced into Xenopus laevis
induces retinal degeneration and shifts localization of
the protein from Golgi and post-Golgi membranes to
the cytoplasm [17].
Though many Rab proteins are well studied, the
precise localization and function of RAB39B are just
beginning to emerge. RAB39B is neuron-specific and
plays a role in synapse formation and maintenance
[11]. Recent evidence suggests that one function of
RAB39B, through its interaction with protein interacting
with C-kinase 1 (PICK1), is to regulate the subunit com-
position of heterotetrameric AMPA receptors [18]. In the
absence of RAB39B, AMPA receptor composition shifts
towards non GluA2-containing Ca2+-permeable forms.
The resulting alteration in synaptic activity has been
posited to underlie the lifelong intellectual disability and
Fig. 3 Effect of p.G192R on RAB39B expression and localization in SK-N-BE(2)C cells. a Western blot of human neuroblastoma (SK-N-BE(2)C) cells
transfected with a vector that was empty (mock), or contained a wild-type or mutant (p.G192R) construct. There was no significant difference in
protein expression between wild-type and mutant RAB39B (Student's t-test, p > 0.05. b Immunofluorescent microscopy of retinoic acid-differentiated
SK-N-BE(2)C cells transfected with wild-type or mutant (p.G192R) GFP-tagged RAB39B. Wild-type protein was seen within the cytoplasm and at the
plasma membrane where it co-localized with epidermal growth factor receptor (EGFR; blue arrows). Although mutant RAB39B protein was also
apparent in the cytoplasm, it less often co-localized with EGFR (white arrows). The scale bar corresponds to 10 μm. c Immunoblot analysis of fractionated
protein extracts performed on SK-N-BE(2)C cells transfected with a vector that was empty (mock), or contained GFP-tagged wild-type or mutant RAB39B.
Double asterisks indicate a significant difference (p< 0.01) by Student’s t-test (n = 3 replicates)
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behavioral problems seen with loss-of-function mutations
in RAB39B. However, the mechanism by which dysregula-
tion of RAB39B leads to the selective neurodegenerative
changes seen in PD is not yet known. Our discovery that
p.G192R results in a “pure” PD phenotype provides an op-
portunity to address this important question by examining
the effects of this mutation in model systems in future
studies.
Conclusions
Our findings implicate RAB39B, an essential regulator of
vesicular-trafficking, in clinically typical PD. Loss-of-
function mutations in this gene were previously shown
to cause X-linked recessive mental retardation sometimes
accompanied by autism spectrum disorder, and members
of two such families were later shown to develop atypical
parkinsonism. However, the phenotype in our family is
classical, levodopa-responsive PD and both males and
females are affected. We present in vitro data that provide
a potential explanation for the substantial difference in
phenotype between our family and those reported else-
where. Unlike previously reported mutations which result
in a complete loss of protein expression, the mutation that
we have discovered (p.G192R) does not alter the overall
amount of protein expressed but rather its intracellular
localization. Our results suggest that dysregulation of
RAB39B, which is thought to mediate vesicular transport,
can lead to selective neurodegenerative changes in the
absence of lifelong cognitive/behavioral dysfunction,
and have important implications for future research.
Methods
Exome sequencing
The exome was captured using the SeqCap EZ Exome
v3.0 kit (Roche/Nimblegen, Madison, WI) and sequenced
with 100-base pair (bp) paired-end reads on a HiSeq2500
(Illumina, San Diego, CA) to achieve a mean coverage of
80-100X. Sequence reads were mapped to the human
reference genome (GRCh37) using the Burrows-Wheeler
Aligner. Variants were jointly called using the GATK
HaplotypeCaller following the developer’s recommended
best practices [8] (https://www.broadinstitute.org/gatk/
guide/best-practices) and annotated with SnpEff [19] based
on the RefSeq gene set (http://www.ncbi.nlm.nih.gov/
refseq). We flagged variants failing to meet the quality
thresholds described by the GATK “Best Practices” of
QD (Quality by Depth) < 2.0, FS (FisherStrand; Fisher’s
exact test for strand bias) > 60.0, MQ (Mapping Quality;
overall mapping quality of reads averaged over all sam-
ples) < 40.0, HaplotypeScore (probability that reads flank-
ing a variant can be explained by ≤ 2 haplotypes) > 13.0,
MQRankSum (comparison of mapping qualities of reads
for reference versus alternate allele) < -12.5, and Read-
PosRankSum (measure of bias in position within reads
between reference and alternate allele) < -8.0. We ex-
cluded alleles that occurred at a frequency >1 % in 515
unrelated white controls selected from the NHLBI Ex-
ome Sequencing Project [6, 7]. Finally, we used cus-
tom software to analyze variants that passed all filters
to identify alleles that segregated with disease.
Sanger sequencing and genotyping
Sanger sequencing was used to confirm and genotype
candidate variants in all available members of the pedi-
gree. We also sequenced the entire RAB39B coding region
and intron-exon boundaries in the probands from PaGeR
Cohort I (n = 203) and in the subset of patients from
Cohort II (n = 384) who reported a family history of PD.
Sequencing was performed using the Applied Biosystems
Big-Dye Terminator v3.1 Cycle Sequencing Kit on an ABI
PRISM 3130 genetic analyzer (Applied Biosystems, Foster
City, CA) as described elsewhere [20]. Sequence data were
base-called, aligned, and scanned for variation using
Mutation Surveyor (SoftGenetics, State College, PA).
RAB39B p.G192R was genotyped in the remainder of
PaGeR Cohort II using a custom TaqMan assay.
Protein expression assays
Two myc-tagged constructs encoding either wild type or
mutant (p.G192R) RAB39B protein were created using
the vector pcDNA 3.1/myc-His (Invitrogen Life Tech-
nologies, Carlsbad, CA). Rat pheochromocytoma (PC12)
and human neuroblastoma (SK-N-BE(2)C) cells were
grown and transfected with wild type or mutant con-
structs using either a retrovirus (pCL Vector System,
Orbigen, San Diego, CA) for PC12 cells or Lipofectamine
(Invitrogen) for SK-N-BE(2)C cells using previously de-
scribed methods [21]. After 24 h the cells were lysed, and
the lysates were subjected to 10 % sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and transferred to
a polyvinylidene difluoride membrane (Bio-Rad Laborator-
ies, Hercules, CA). The membranes were incubated with an
anti-myc antibody (Roche Life Sciences, Branford, CT) and
detection was achieved using the Novex ECL chemilu-
minescent substrate reagent kit (Invitrogen).
Protein trafficking experiments
PC12 cells were transfected with a wild type or mutant
(p.G192R) myc-tagged RAB39B construct as described
in the previous section and differentiated with nerve
growth factor (NGF) for 4 days. The cells were fixed in 4 %
paraformaldehyde and then incubated overnight at 4 °C
with rabbit anti-myc and anti-chromogranin A antibodies.
SK-N-BE(2)C cells were transfected with GFP-tagged wild
type or mutant RAB39B constructs (pEGFP-N1 vector;
Clontech Laboratories, Mountain View, CA) using Lipo-
fectamine. After retinoic acid-induced differentiation for
4 days the cells were fixed in 4 % paraformaldehyde and
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incubated overnight at 4 °C with anti-epidermal growth
factor receptor (anti-EGFR) antibody (a plasma membrane
marker; Cell Signaling Technology, Danvers, MA) using
methods described elsewhere [22]. Hoechst 33342 was
used for counterstaining and confocal analysis was
performed using an Olympus IX81 microscope.
Subcellular fractionation
SK-N-BE(2)C cells were transfected with GFP-tagged
wild type or mutant RAB39B constructs as described in
the previous section. After 24 h the cells were lysed and
membrane and cytoplasmic fractions were prepared
using the Subcellular Protein Fractionation kit for
Cultured Cells (Thermo Scientific, Rockford, IL) accor-
ding to the manufacturer’s recommendations. The frac-
tionated lysates were subjected to 10 % sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and transferred
to a polyvinylidene difluoride membrane. The membranes
were incubated with an anti-GFP antibody (Santa Cruz
Biotechnology). Images of western blots were captured
using the ChemiDoc XRS system (Bio-Rad Laboratories)
and scanned films were quantified using Image J software
(http://rsb.info.nih.gov/ij/).
Additional file
Additional file 1: Figure S1. Pedigrees with variants of unknown
significance. Pedigrees in which the RAB39B (A) c.428C>G (p.A143G) and
(B) c.624_626delGAG (p.R209del) variants were observed. Individuals
affected with Parkinson’s disease are represented with black symbols,
unaffected individuals with open symbols. Age at onset is indicated
immediately below each symbol, followed by age at last clinical
evaluation. Wt = wild type; Mut = mutation. (PDF 35 kb)
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
IFM and CPZ had full access to all of the data in the study and take responsibility
for the integrity of the data and the accuracy of the data analysis. Study concept
and design: IFM, CPZ. Acquisition of data: YJ, C-HK, DSH, MOD, AS, PA, JWR, OK,
DRS, KAC, SAF, AJE, FJR, DSH, IL, JBL, DY, MI-M, EM, TT, BAC, S-CH, K-SK . Analysis
and interpretation of data: IFM, YJ, C-HK, DSH, MOD, KLE, KLE, CPZ. Drafting of
the manuscript: IFM, CPZ. Critical revision of the manuscript for important
intellectual content: YJ, C-HK, DSH, MOD, AS, PA, JWR, OK, DRS, KAC, SAF,
AJE, FJR, DSH, IL, JBL, DY, MI-M, EM, TT, BAC, S-CH, KLE, K-SK. All authors
read and approved the final manuscript.
Acknowledgments
This work was supported by grants from the National Institutes of Health
(P50 NS062684, R01 NS065070, R01 NS084869) and the Department of
Veterans Affairs (1I01BX000531), and by a gift from the Dolsen Foundation.
We thanks all of the individuals who participated in the study and Drs.
Jennifer Witt and Rosalind Chuang for assistance with patient recruitment.
Author details
1Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA.
2Department of Neurology, University of Washington School of Medicine,
Seattle, WA, USA. 3Molecular Neurobiology Laboratory, Department of
Psychiatry and Program in Neuroscience, McLean Hospital/Harvard Medical
School, Belmont, MA, USA. 4Department of Psychiatry and Behavioral
Sciences, University of Washington, Seattle, WA, USA. 5Department of
Pathology, University of Washington, Seattle, WA, USA. 6Booth Gardner
Parkinson’s Care Center, Evergreen Hospital Medical Center, Kirkland, WA,
USA. 7Virginia Mason Medical Center, Seattle, WA, USA. 8Department of
Neurology, University of Colorado, Denver, USA. 9Department of Neurology,
University of Utah, Salt Lake City, UT, USA. 10Parkinson’s Disease Research,
Education, and Clinical Center, Portland Veterans Affairs Medical Center,
Portland, OR, USA. 11Department of Neurology, Oregon Health and Science
University, Portland, OR, USA. 12Department of Neurology, Emory University
School of Medicine, Atlanta, GA, USA. 13Department of Neurology and
Rehabilitation Medicine, University of Cincinnati, Cincinnati, OH, USA.
14Division of Neurology at Greenville Health System and the University of
South Carolina Medical School-Greenville, Greenville, SC, USA. 15Samuel
Stratton Veterans Affairs Medical Center, Albany, NY, USA. 16Movement
Disorder Center, Department of Neurosciences, University of California, San
Diego, CA, USA. 17Lou Ruvo Center for Brain Health, Cleveland Clinic,
Cleveland, OH, USA. 18Neurogenetics Research Center, Instituto Nacional de
Ciencias Neurologicas, Lima, Peru. 19Department of Epidemiology, University
of California, Irvine, CA, USA.
Received: 31 July 2015 Accepted: 17 September 2015
References
1. Trinh J, Farrer M. Advances in the genetics of Parkinson disease. Nat Rev
Neurol. 2013;9(8):445–54.
2. Singleton AB. Exome sequencing: a transformative technology. Lancet
Neurol. 2011;10(10):942–6.
3. Zimprich A, Benet-Pages A, Struhal W, Graf E, Eck SH, Offman MN, et al. A
mutation in VPS35, encoding a subunit of the retromer complex, causes
late-onset Parkinson disease. Am J Hum Genet. 2011;89(1):168–75.
4. Vilarino-Guell C, Rajput A, Milnerwood AJ, Shah B, Szu-Tu C, Trinh J, et al.
DNAJC13 mutations in Parkinson disease. Hum Mol Genet. 2014;23(7):1794–801.
5. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis
of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry.
1988;51(6):745–52.
6. Weeke P, Mosley JD, Hanna D, Delaney JT, Shaffer C, Wells QS, et al. Exome
sequencing implicates an increased burden of rare potassium channel
variants in the risk of drug-induced long QT interval syndrome. J Am Coll
Cardiol. 2014;63(14):1430–7.
7. Tennessen JA, Bigham AW, O'Connor TD, Fu W, Kenny EE, Gravel S, et al.
Evolution and functional impact of rare coding variation from deep
sequencing of human exomes. Science. 2012;337(6090):64–9.
8. Carson AR, Smith EN, Matsui H, Braekkan SK, Jepsen K, Hansen JB, et al.
Effective filtering strategies to improve data quality from population-based
whole exome sequencing studies. BMC Bioinformatics. 2014;15:125.
9. Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general
framework for estimating the relative pathogenicity of human genetic
variants. Nat Genet. 2014;46(3):310–5.
10. Ferreira JP, Peacock RW, Lawhorn IE, Wang CL. Modulating ectopic gene
expression levels by using retroviral vectors equipped with synthetic
promoters. Syst Synth Biol. 2011;5(3-4):131–8.
11. Giannandrea M, Bianchi V, Mignogna ML, Sirri A, Carrabino S, D'Elia E, et al.
Mutations in the small GTPase gene RAB39B are responsible for X-linked
mental retardation associated with autism, epilepsy, and macrocephaly. Am
J Hum Genet. 2010;86(2):185–95.
12. Vanmarsenille L, Giannandrea M, Fieremans N, Verbeeck J, Belet S, Raynaud M,
et al. Increased dosage of RAB39B affects neuronal development and could
explain the cognitive impairment in male patients with distal Xq28 copy
number gains. Hum Mutat. 2014;35(3):377–83.
13. Wilson GR, Sim JC, McLean C, Giannandrea M, Galea CA, Riseley JR, et al.
Mutations in RAB39B cause X-linked intellectual disability and early-onset
Parkinson disease with alpha-synuclein pathology. Am J Hum Genet.
2014;95(6):729–35.
14. Hutagalung AH, Novick PJ. Role of Rab GTPases in membrane traffic and
cell physiology. Physiol Rev. 2011;91(1):119–49.
15. Schwartz SL, Cao C, Pylypenko O, Rak A, Wandinger-Ness A. Rab GTPases at
a glance. J Cell Sci. 2007;120(Pt 22):3905–10.
16. Pfeffer SR. Structural clues to Rab GTPase functional diversity. J Biol Chem.
2005;280(16):15485–8.
17. Moritz OL, Tam BM, Hurd LL, Peranen J, Deretic D, Papermaster DS. Mutant
rab8 Impairs docking and fusion of rhodopsin-bearing post-Golgi
Mata et al. Molecular Neurodegeneration  (2015) 10:50 Page 7 of 8
membranes and causes cell death of transgenic Xenopus rods. Mol Biol
Cell. 2001;12(8):2341–51.
18. Mignogna ML, Giannandrea M, Gurgone A, Fanelli F, Raimondi F, Mapelli L,
et al. The intellectual disability protein RAB39B selectively regulates GluA2
trafficking to determine synaptic AMPAR composition. Nat Commun.
2015;6:6504.
19. Cingolani P, Platts A, le Wang L, Coon M, Nguyen T, Wang L, et al. A
program for annotating and predicting the effects of single nucleotide
polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster
strain w1118; iso-2; iso-3. Fly (Austin). 2012;6(2):80–92.
20. Tsuang D, Leverenz JB, Lopez OL, Hamilton RL, Bennett DA, Schneider JA,
et al. GBA mutations increase risk for Lewy body disease with and without
Alzheimer disease pathology. Neurology. 2012;79(19):1944–50.
21. Kim CH, Leung A, Huh YH, Yang E, Kim DJ, Leblanc P, et al. Norepinephrine
deficiency is caused by combined abnormal mRNA processing and
defective protein trafficking of dopamine beta-hydroxylase. J Biol Chem.
2011;286(11):9196–204.
22. Jang Y, Lee MH, Lee J, Jung J, Lee SH, Yang DJ, et al. TRPM2 mediates the
lysophosphatidic acid-induced neurite retraction in the developing brain.
Pflugers Arch. 2014;466(10):1987–98.
23. Kelley LA, Sternberg MJ. Protein structure prediction on the Web: a case
study using the Phyre server. Nat Protoc. 2009;4(3):363–71.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Mata et al. Molecular Neurodegeneration  (2015) 10:50 Page 8 of 8
